Abstract
We performed a retrospective analysis of costs and time to treatment (TT) of 150 culture-confirmed TB cases: 100 sputum smear (SS) (+) and 50 SS(−). This group underwent GeneXpert® (GX) assay. Expenditures and TT of SS(−)/GX(+) cases were inferred from the SS(+) group. GX detected 68% of SS(−) cases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
